Study Of Asthma In Patients Of African Descent

Phase 4

Completed

• Conditions: Asthma

• Registration Number: NCT00102765
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11
• Study First Submitted: 2005-02-01
• Study First Submitted QC: 2005-02-01
• Study First Posted: 2005-02-02
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-16
• Last Update Posted: 2017-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 479

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Asthma exacerbation rate per patient per year

Secondary Outcome Measures

Name	Time	Method
Morning peak flow measurement, percent of asthma symptom-free days, percent of albuterol-free days

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Madison, Wisconsin, United States